Moderate to Severe Acne Pipeline Landscape Analysis, 2024, Featuring Emerging Therapies ASC40 (Ascletis Pharma), BTX 1503 (Botanix Pharmaceuticals), and More

Core Insights - The global therapeutic market for Moderate to Severe Acne is poised for transformation with over 10 pharmaceutical companies developing more than 10 pipeline drugs aimed at innovating acne treatments [1][3] Group 1: Emerging Therapies - ASC40 by Ascletis Pharma Inc. is a fatty acid synthase inhibitor that targets lipogenesis, a key factor in sebum production related to acne [2] - Botanix Pharmaceuticals' BTX 1503 utilizes the novel Permetrex™ drug delivery technology to address multiple causal factors of acne [2] Group 2: Future Outlook - The report indicates a significant shift towards more effective treatment regimens for Moderate to Severe Acne, driven by advancements in clinical studies and strategic collaborations [3] - Increased disease awareness and healthcare investments globally are expected to expand the market for acne treatments [3] Group 3: Key Companies - Notable companies involved in the development of acne treatments include Ascletis Pharma Inc., Botanix Pharmaceuticals, Biofrontera Bioscience GmbH, Novartis, BIOPHARMX, INC., DERMATA THERAPEUTICS, INC., AnaptysBio, and VYNE Therapeutics Inc. [4]